Overview

A Placebo-controlled, Phase 2 Trial to Evaluate OPC 67683 in Patients With Pulmonary Sputum Culture-positive, Multidrug-resistant Tuberculosis (TB)

Status:
Completed
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
This is a clinical trial to evaluate the safety and efficacy of OPC-67683 in the treatment of multidrug resistant tuberculosis (MDR TB) for 56 days. In addition to an optimized background regimen (OBR).patients will receive will be randomized to: - 100 mg OPC-67683 BID - 200 mg OPC-67683 BID - placebo BID After 56 days subjects will complete their OBR.
Phase:
Phase 2
Details
Lead Sponsor:
Otsuka Pharmaceutical Development & Commercialization, Inc.